Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18–64 years

Since the authorization of the Moderna mRNA COVID-19 vaccine, real-world evidence has indicated its effectiveness in preventing COVID-19 cases. However, increased cases of mRNA vaccine-associated myocarditis/pericarditis have been reported, predominantly in young adults and adolescents. The Food and...

Descripción completa

Detalles Bibliográficos
Autores principales: Yogurtcu, Osman N., Funk, Patrick R., Forshee, Richard A., Anderson, Steven A., Marks, Peter W., Yang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Regular paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234830/
https://www.ncbi.nlm.nih.gov/pubmed/37324525
http://dx.doi.org/10.1016/j.jvacx.2023.100325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234830/
https://www.ncbi.nlm.nih.gov/pubmed/37324525
http://dx.doi.org/10.1016/j.jvacx.2023.100325

Ejemplares similares